IBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
iBio Inc is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, absence of significant trading trends, and neutral technical indicators make it a less compelling investment opportunity. Additionally, the company is over 12 months away from clinical data, and there are no immediate catalysts to drive significant price appreciation.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 44.505, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. The stock is trading below the pivot level of 2.679, with key support at 2.37 and resistance at 2.989.
The company's extended half-life antibody platform has potential in obesity and metabolic indications.
The company's revenue has dropped to zero, and EPS has declined significantly. The company is over 12 months away from clinical data, and there are no recent news or significant trading trends to support a bullish sentiment.
In 2026/Q2, revenue dropped to $0 (-100% YoY), net income improved to -$8.993M (+106.07% YoY), and EPS declined to -0.3 (-37.5% YoY). Gross margin remained at 100%. Overall, the financial performance is weak, with no revenue generation.
Analysts have given Buy and Outperform ratings with price targets of $5 to $7. However, the stock's movement is expected to be influenced by INHBE siRNA companies, and clinical data is over a year away.
